Qualigen Therapeutics, Inc.

DB:7R9 Stock Report

Market Cap: €4.1m

Qualigen Therapeutics Balance Sheet Health

Financial Health criteria checks 2/6

Qualigen Therapeutics has a total shareholder equity of $-4.3M and total debt of $1.7M, which brings its debt-to-equity ratio to -39%. Its total assets and total liabilities are $534.4K and $4.8M respectively.

Key information

-39.0%

Debt to equity ratio

US$1.67m

Debt

Interest coverage ration/a
CashUS$118.69k
Equity-US$4.28m
Total liabilitiesUS$4.81m
Total assetsUS$534.41k

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 7R9 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 7R9 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 7R9 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 7R9's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7R9 has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: 7R9 is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies